Tempus AI Contracts Surge Past $1.1 Billion as Pharma Giants Embrace AI Platform
Tempus AI’s contract value milestone reflects accelerating adoption by pharmaceutical heavyweights. The company secured 70+ data agreements in 2025 with AstraZeneca, GSK, and Merck driving growth.
Diagnostics revenue nearly doubled to $955 million, powered by a 111% year-over-year surge. Oncology testing volumes ROSE 26%, while hereditary testing jumped 29%.
Wall Street maintains a Moderate Buy rating with a $87 median price target—29.77% upside potential. The stock gained amid broader crypto market momentum, though no direct coin or exchange correlations were identified in this healthcare AI development.